Skip to main content
SpringerLink
Log in

Clinically Significant Drug Interactions with the Oral Anticoagulants

  • Review Article
  • Drug Experience
  • Published:
Drug Safety Aims and scope Submit manuscript

Summary

Oral anticoagulants were introduced in the late 1940s and remain widely used today. Indications include prevention of thrombosis associated with atrial fibrillation, structural cardiac diseases and following prosthetic valvular replacement. They have been used for both treatment and prophylaxis of deep venous thrombosis and in efforts to decrease the frequency and rate of second myocardial infarction. These compounds include the coumarin derivatives [dicoumarol (bishydroxycoumarin), phenprocoumon, nicoumalone (acenocoumarol)] and the indanedione derivatives (diphenadione, phenindione, anisindione) which, because of adverse reactions, are largely unavailable. The oral anticoagulants, and warfarin in particular, are highly interactive with other drugs. Mechanisms of those interactions include both pharmacokinetic and pharmacodynamic mechanisms and may result in either hyper- or hypoprothrombinaemia. Because their principal adverse reaction is haemorrhage, and interactions are widespread across many therapeutic specialties, it becomes imperative for the practising physician to be aware of the possibility of interaction whenever these agents are coadministered with other drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ahmad S. Lovastatin warfarin interaction. Archives of Internal Medicine 150: 2407, 1990

    PubMed  CAS  Google Scholar 

  • Almog S, Martinowitz U, Halkin H, Bank HZ, Farfel Z. Complex interactions of rifampin and warfarin. Southern Medical Journal 81: 1304–1306, 1988

    PubMed  CAS  Google Scholar 

  • Armstrong G, Bed MF, Scahill S. Warfarin potentiated by proguanil. British Medical Journal 303: 789, 1991

    Google Scholar 

  • Baciewicz AM, Morgan PJ. Ranitidine-warfarin interaction. Annals of Internal Medicine 112: 76–77, 1990

    PubMed  CAS  Google Scholar 

  • Bailey RR, Reddy J. Potentiation of warfarin action by sulfinpyrazone. Lancet 1: 254, 1980

    PubMed  CAS  Google Scholar 

  • Banfield C, O’Reilly R, Chan E, Rowland M. Phenylbutazone-warfarin interactions in man: further sterochemical and metabolic considerations. British Journal of Clinical Pharmacology 16: 669–675, 1983

    PubMed  CAS  Google Scholar 

  • Bartle WR, Blakely JA. Potentiation of warfarin anticoagulation by acetaminophen. Journal of the American Medical Association 265: 1260, 1991

    PubMed  CAS  Google Scholar 

  • Bechtold H. Andressy K, Jahnchen E, et al. Evidence for impaired hepatic vitamin K1 metabolism in patients treated with N-methylthiotetrazole cephalosporins. Thrombosis and Haemostatsis 51: 358–361, 1984

    CAS  Google Scholar 

  • Bell WR, Anderson KC, Noe DA, Silver BA. Reduction in the plasma clearance rate of Warfarin induced by cimetidine. Archives of Internal Medicine 146: 2325–2328, 1986

    PubMed  CAS  Google Scholar 

  • Biggs R, Bangham DR. Standardization of the one stage prothrombin time test for the control of anticoagulant therapy: the availability and use of thromboplastin reference preparations. Thrombosis et Diathesis Heamorrhagica 26: 203, 1971

    CAS  Google Scholar 

  • Bijornsson TD, Meffin PJ, Swezey S, Blaschke TF, Clofibrate displaces warfarin from plasma proteins in man: an example of a pure displacement interaction. Journal of Pharmacology and Experimental Therapeutics 210: 316–321, 1979

    Google Scholar 

  • Bingle J, Shine I. Phenindione sensitivity. Lancet 2: 377–379, 1959

    PubMed  CAS  Google Scholar 

  • Black D, Evans J, Seaton T, Gidal B, McDonnell N, et al. Evaluation of the effect of fluconazole on the steroselective metabolism of warfarin. ASHP Midyear Clinical Meeting 26: P–474R, 1991

    Google Scholar 

  • Blickstein D, Shaklai M, Inbal A. Warfarin antagonism by avocado. Lancet 337: 914–915, 1991

    PubMed  CAS  Google Scholar 

  • Braverman SE, Marino MT. Sucralfate-warfarin Interactions. Drug Intelligence and Clinical Pharmacy 22: 913, 1988

    PubMed  CAS  Google Scholar 

  • Breckenridge A, Orme ML’E. Plasma half lives and the pharmacological effect of the enantiomers of warfarin in rats. Life Sciences 11: 337–345, 1972

    CAS  Google Scholar 

  • Butt HR, Allen EV, Bollman JL. A preparation from spoiled sweet clover (3,3′-methylene-bis-4 hydroxycoumarin) which prolongs coagulation time of blood: preliminary report of experimental and clinical studies. Mayo Clinic Proceedings 16: 388–395, 1941

    CAS  Google Scholar 

  • Chow WH, Cheung KL, Ling HM, See T. Potentiation of warfarin anticoagulation by topical methylsalicylate ointment. Journal of the Royal Society of Medicine 82: 501–502, 1989

    PubMed  CAS  Google Scholar 

  • Christensen LK, Skovsted L. Inhibition of drug metabolism by chloramphenocol. Lancet 2: 1397, 1969

    PubMed  CAS  Google Scholar 

  • Corrigan JJ. The effect of vitamin E on warfarin-induced vitamin K deficiency. Annals of the New York Academy of Sciences 393: 361, 1982

    PubMed  CAS  Google Scholar 

  • Corrigan Jr JJ, Marcus FI. Coagulopathy associated with vitamin E ingestion. Journal of the American Medical Association 230: 1300, 1974

    PubMed  Google Scholar 

  • Crussell-Porter LL, Rindone JP, Ford MA, Jaskar DW. Low-dose fluconazole therapy potentiates the hypoprothrombinemic response of warfarin sodium. Archives of Internal Medicine 153: 102–104, 1993

    PubMed  CAS  Google Scholar 

  • Cuddy PG, Loftus LS. Influence of mitotane on the hypoprothrombinemic effect of warfarin. Southern Medical Journal 79: 387–388, 1986

    PubMed  CAS  Google Scholar 

  • Danoes EA. Apparent potentiation of warfarin activity by tetracycline. Clinical Pharmacology 11: 806–808, 1992

    Google Scholar 

  • Davis RL, Berman Jr W, Wernly JA, Kelly HW. Warfarin-nafcillin interaction. Journal of Pediatrics 118: 300–303, 1991

    PubMed  CAS  Google Scholar 

  • Denbow CE, Fraser HS. Clinically significant hemorrhage due to warfarin-carbamazepine. Southern Medical Journal 83: 981, 1990

    PubMed  CAS  Google Scholar 

  • de Teresa E. Interaction between anticoagulants and contraceptives: an unsuspected finding. British Medical Journal 2: 1260, 1979

    PubMed  Google Scholar 

  • Dugoni-Kramer BM. Ciprofloxacin-warfarin interaction. DICP: Annals of Pharmacotherapy 25: 1397, 1991

    PubMed  CAS  Google Scholar 

  • Eckman MH, Levine HJ, Pauker SG. Effect of laboratory variation in the prothrombin time ratio on the results of oral anticoagulant therapy. New England Journal of Medicine 329: 696–702, 1993

    PubMed  CAS  Google Scholar 

  • Elwin CE, Torngren M. Simultaneous intake of warfarin and stanozolol as cause of hemorrhage in a patient. Lakartidningen 85: 3290, 1988

    PubMed  CAS  Google Scholar 

  • Flessner MF, Knight H. Prolongation of prothrombin time and severe gastrointestional bleeding associated with combined use of warfarin and ketoprofen. Journal of the American Medical Association 259: 353, 1988

    PubMed  CAS  Google Scholar 

  • Fossella FV, Lippman SM, Seitz DE, Alberts DS, Taylor CW. Hypoprothrombinemia from coadministration of sulofenur (LY 186641) and warfarin: report of three cases. Investigational New Drugs 9: 357–359, 1991

    PubMed  CAS  Google Scholar 

  • Fraser GL, Miller M, Kane K. Warfarin resistance associated with nafcillin therapy. American Journal of Medicne 87: 237–238,1989

    CAS  Google Scholar 

  • Freedman MD. Oral anticoagulants: pharmacodynamics, clinical indications, and adverse effects. Journal of Clinical Pharmacology 32: 196–209, 1992

    PubMed  CAS  Google Scholar 

  • Freedman MD. Pharmacodynamics, clinical indications and adverse affects of heparin. Journal of Clinical Pharmacology 32: 584–596, 1992

    PubMed  CAS  Google Scholar 

  • Goulbourne LA, MacLeod DAD. An interaction between danazol and warfarin: case report. British Journal of Obstetrics and Gynaecology 88: 950–951, 1981

    PubMed  CAS  Google Scholar 

  • Green AE, Hort JF, Korn HE, Leach H. Potentation of warfarin by azapropazone. British Medical Journal 1: 1532, 1977

    PubMed  CAS  Google Scholar 

  • Hall G, Lind MJ, Huang M, Moore A, Gane A, et al. Intravenous infusions of ifosfamide/mesna and perturbation of warfarin anticoagulant control. Postgraduate Medical Journal 66: 860–861, 1990

    PubMed  CAS  Google Scholar 

  • Hansen JM, Siersbaek-Nielsen, K, Skovsted, L. Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clinical Pharmacology and Therapeutics 12: 539–543, 1971

    PubMed  CAS  Google Scholar 

  • Hassell D, Utt JK. Suspected interactions: warfarin and erythromcyin. Southern Medical Journal 78: 10156, 1986

    Google Scholar 

  • Hauser VM, Rozek SL. Effect of warfarin on the activated partial thromboplastin time. Drug Intelligence and Clinical Pharmacology 20: 964–967, 1986

    CAS  Google Scholar 

  • Hemimark LD, Winkers L, Kunze K, Gibaldi M, Eddy AC, et al. The mechanism of the interaction between amiodarone and warfarin in humans. Clinical Pharmacology and Therapeutics 51: 398–407, 1992

    Google Scholar 

  • Hill DB. Drug interaction between digoxin immune FAB (digibind) and warfarin. Southern Medical Journal 83 (Suppl. 2): 31, 1990

    Google Scholar 

  • Hirsch J. Oral anticoagulant drugs. New England Journal of Medicine 324: 1865–1875, 1991

    Google Scholar 

  • Hirsh J, Poller L, Deykin D, Levine M, Dalen JE. Optimal therapeutic range for oral anticoagulants. Chest 95 (Suppl.): 5S–11S, 1989

    PubMed  CAS  Google Scholar 

  • Holt RJ, Freytes CO. Familial warfarin resistance. Drug Intelligence and Clinical Pharmacy 17: 281, 1983

    PubMed  CAS  Google Scholar 

  • Huebner CF, Link KP. Studies on the hemorrhagic sweet clover disease. Journal of Biological Chemistry 138: 529–534, 1941

    CAS  Google Scholar 

  • Hume R. Interaction of ascorbic acid and warfarin. Journal of the American Medical Association 219: 1479, 1972

    PubMed  CAS  Google Scholar 

  • Hunt BA, Sax MJ, Chretien SD, Gray DR, Frank WO, et al. Steroselective alternations in the pharmacokinetics of warfarin enantimoers with two cimetidine dose regimens. Pharmacotherapy 9: 184, 1989

    CAS  Google Scholar 

  • Jahnchen E, Meinertz T, Gilfrich HJ, Kersting F, Groth U. Enhanced elimination of warfarin during treatment with cholestyramine. British Journal of Clinical Pharmacology 5: 437–440, 1978

    PubMed  CAS  Google Scholar 

  • Jassal SV. Warfarin potentiated by proguanil. British Medical Journal 303: 789, 1991

    Google Scholar 

  • Jones NL. Hepatitis due to phenindione sensitivity. British Medical Journal 2: 504–506, 1960

    PubMed  CAS  Google Scholar 

  • Justice JL, Kline SS. Analgesics and warfarin. A case that brings up questions and cautions. Postgraduate Medicine 83: 217–218, 1988

    PubMed  CAS  Google Scholar 

  • Kalowski S, Kincaid-Smith P. Interaction of dipyridamole with anticoagulants in the treatment of glomerulonephritis. Medical Journal of Australia 2: 164, 1973

    PubMed  CAS  Google Scholar 

  • Kaplinksy N, Thaler M, Militianu J, Frankin O. Transient pulmonary infiltrates associated with warfarin. Journal of the American Medical Association 243: 513–514, 1980

    Google Scholar 

  • Karlson B, Leijd B, Hellstrom K. On the influence of vitamin K-rich vegtables and wine on the effectiveness of warfarin treatment. Acta Medica Scandinavica 220: 347–350, 1986

    PubMed  CAS  Google Scholar 

  • Kates RE, Yee YG, Kirsten EB. Interaction between warfarin and propafenone in healthy volunteer subjects. Clinical Pharmacology and Therapetics 42: 305–311, 1987

    CAS  Google Scholar 

  • Kaufman JM, Fauver Jr HE. Potentiation of warfarin by trimethoprim-sulfamethoxazole. Urology 16: 601–603, 1980

    PubMed  CAS  Google Scholar 

  • Kearns Jr PJ, Imai K, Kelsey T, O’Reilly RA. Vitamin K and warfarin drug-nutrient interaction. Abstract. Clinical Research 35: 773A, 1987

    Google Scholar 

  • Kearns PJ, O’Reilly RA. Bioavailability of warfarin in a patient with severe short bowel syndrome. Journal of Parenteral and Entereral Nutrition 10: 100–101, 1986

    Google Scholar 

  • Kerin NZ, Blevins RD, Goldman L, Faitel K, Rubenfire M. The incidence, magnitude, and time course of the amiodarone-warfarin interaction. Archives of Internal Medicine 148: 1779–1781, 1988

    PubMed  CAS  Google Scholar 

  • Koren JF, Cochran DL, Lanes RL. Tolmentin-warfarin interaction. American Journal of Medicine 82: 1278–1279, 1987

    PubMed  CAS  Google Scholar 

  • Krstenansky PM, Jones WN, Garewal HS. Effect of dicloxacillin sodium on the hypoprothrombinemic response to warfarin sodium. Clinical Pharmacology 6: 804–806, 1987

    CAS  Google Scholar 

  • Lader E, Yang L, Clarke A. Wafarin dosage and vitamin K in Osmolite. Annals of Internal Medicine 93: 373–374,1980

    PubMed  CAS  Google Scholar 

  • Leor J, Matetzki S. Oflaxacin and warfarin. Annals of Internal Medicine 109: 761, 1988

    PubMed  CAS  Google Scholar 

  • Leor J, Levartowsky D, Sharon C. Interaction between nalidixic acid and warfarin. Annals of Internal Medicine 107: 601, 1987

    PubMed  CAS  Google Scholar 

  • Link KP. The anticoagulant from spoiled sweet clover. Harvey Lectures 39: 162–216, 1943–1944

    Google Scholar 

  • Link KP. Discovery of dicumarol and its sequels. Circulation 19: 97–107, 1959

    PubMed  CAS  Google Scholar 

  • Linville T. Matanin D. Norfloxacin and warfarin. Annals of Internal Medicine 110: 751–752, 1989

    PubMed  CAS  Google Scholar 

  • Linville D, Emory C, Graves L. Ciprofloxacin and warfarin interaction. American Journal of Medicine 90: 765, 1991

    PubMed  Google Scholar 

  • Littleton Jr F. Warfarin and topical salicylates. Journal of the American Medical Association 263: 2888, 1990

    PubMed  Google Scholar 

  • Lodwick R, McConkey B, Brown AM, Beeley L. Life threatening interactions between tamoxifen and warfarin. British Medical Journal 295: 1141, 1987

    PubMed  CAS  Google Scholar 

  • Loftin JP, Vesell ES. Interactions between sulindace and warfarin: different results in normal subjects and in an unusual patient with potassium-losing renal tubular defect. Journal of Clinical Pharmacology 19: 733–742, 1979

    PubMed  CAS  Google Scholar 

  • Long M, Hurn M, Barker NW. Effect of heparin on the prothrombin time. Mayo Clinic Proceedings 21: 225, 1946

    CAS  Google Scholar 

  • Lonning PE, Kvinnsland S, Jahren G. Aminoglutethimide and warfarin. A new important drug interaction. Cancer Chemotherapy and Pharmacology 12: 10–12, 1984

    PubMed  CAS  Google Scholar 

  • Lumholtz B, Siersbaek-Nielsen K, Skovsted L, Kampmann J, Hansen. Sulfamethizole induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism. Clinical Pharmacology and Therapeutics 17: 731–734, 1975

    PubMed  CAS  Google Scholar 

  • Lutomski DM, Palascak JE, Bower RH. Warfarin resistance associated with intravenous lipid administration. Journal of Parenteral and Enterai Nutrition 11: 316–318, 1987

    CAS  Google Scholar 

  • Mallet L, Cooper JW. Prolongation of prothrombin time with the use of piroxicam and warfarin. Canadian Journal of Hospital Pharmacy. 44: 93–94, 1991

    Google Scholar 

  • Martin JE, Lutomski, DM. Warfarin resistance and enterai feedings. Journal of Parenteral and Enterai Nutrition 13: 206–208, 1989

    CAS  Google Scholar 

  • McLeod AD, Burgess C, Drug interaction between warfarin and enoxacin. New Zealand Medical Journal 101: 216, 1988

    PubMed  CAS  Google Scholar 

  • Meeks ML, Mahaffey KW, Katz MD. Danzol increases the anticoagulant effect of warfarin. DICP: Annals of Pharmacotherapy 26: 641–642, 1992

    CAS  Google Scholar 

  • Mott FE, Murphy S, Hunt V. Ciprofloxacin and warfarin. Annals of Internal Medcine 111: 542–543, 1989

    CAS  Google Scholar 

  • Moulds RFW, Fullinfaw RO, Bury RW, Plehwe WE, Jacka N. Investiagation of warfarin-ponalrestat interactions in vitro and in vivo. Clinical and Experimental Pharmacology and Physiology (Suppl.17): 56, 1990

  • Moulds RF, Fullinfaw RO, Bury RW, Plehwe WE, Jacka N, et al. Ponalrestat does not cause a protein binding interaction with wafarin in diabetic patients. British Journal of Clinical Pharmacology 31: 715–718, 1991

    PubMed  CAS  Google Scholar 

  • Niopas I, Toon S, Rowland M. Further insight into the steroselective interactions between warfarin and cimetidine in man. British Journal of Clinical Pharmacology 32: 508–511, 1991

    PubMed  CAS  Google Scholar 

  • O’Reilly RA. Comparative interaction of cimetidine and ranitidine with racemic warfarin in man. Archives of Internal Medicine 144: 989–991, 1984

    PubMed  Google Scholar 

  • O’Reilly RA. Dynamic interactions between disulfiram and separted enantiomorphs of racemic warfarin. Clinical Pharmacology and Therapeutics 29: 332–336, 1981

    PubMed  Google Scholar 

  • O’Reilly RA. Interaction of chronic daily warfarin therapy and rifampin. Annals of Internal Medicne 83: 506–508, 1975

    Google Scholar 

  • O’Reilly RA. Spironolactone and warfarin interaction. Clinical Pharmacology and Therapeutics 27: 198, 1990

    Google Scholar 

  • O’Reilly RA. Studies on the optical enantiomers of sodium warfarin in man. Clinical Research 21: 197A, 1973

    Google Scholar 

  • O’Reilly RA. The pharmacodynamics of the oral anticoagulant drugs. Progress in Hemostasis and Thrombosis 2: 175–213, 1974

    PubMed  Google Scholar 

  • O’Reilly RA. The steroselective interaction of warfarin and metro-nidazole in man. New England Journal of Medicine 295: 354–357, 1976

    PubMed  Google Scholar 

  • O’Reilly RA. Ticrynafen-racemic warfarin interactions: hepatotoxic or steroselective? Clinical Pharmacology and Therapeutics 32: 356–361, 1982

    PubMed  Google Scholar 

  • O’Reilly RA, Aggeler PM, Leong LS. Studies on the coumarin anticoagulant drugs: pharmacodynamics of warfarin in man. Journal of Clinical Investigation 42: 1542–1551, 1963

    PubMed  Google Scholar 

  • O’Reilly RA, Goulart DA. Comparative interactions of sulfinpyrazone and phenylbutazone with racemic warfarin alternation in vivo of free fraction of plasma warfarin. Journal Pharmacology and Experimental Therapeutics 219: 691–694, 1981

    Google Scholar 

  • O’Reilly RA, Goulart DA, Kunze KL, Neal J, Gibaldi M, et al. Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clinical Pharmacology and Therapeutics 51: 656–667, 1992

    PubMed  Google Scholar 

  • O’Reilly RA, Levy G. Kinetics of the anticoagulant bishydroxycoumarin in man. Clinical Pharmacology and Therapeutics 11: 378–384, 1970

    PubMed  Google Scholar 

  • O’Reilly RA, Motley CH. Racemic warfarin and trimethoprim-sulfamethoxazole interactions in humans. Annals of Internal Medicine 91: 34–36, 1979

    PubMed  Google Scholar 

  • O’Reilly RA, Rytand DA. Resistance to warfarin due to unrecognized vitamin K supplementation. New England Journal of Medicine 303: 160–161, 1980

    PubMed  Google Scholar 

  • O’Reilly RA, Trager WF, Motley CH, Howald W. Interactions of secobarbital with warfarin pseudoracemates. Clinical Pharmacology and Therapeutics 28: 187–195, 1980

    PubMed  Google Scholar 

  • Parr MD, Record KE, Griffith GL, Zeok JV, Todd EP. Effect of enterai nutrition on warfarin therapy. Clinical Pharmacology 1: 274–276, 1982

    CAS  Google Scholar 

  • Payne RW. Side-effects of phenindione. British Medical Journal 2: 667, 1960

    Google Scholar 

  • Poller L. INR and the therapeutic range. Biology and Haematology 9: 202–213, 1987

    Google Scholar 

  • Quick AJ. The prothrombin time in hemophilia and obstructive jaundice. Journal of Biological Chemistry 109: 73–74, 1935

    Google Scholar 

  • Qureshi GD, Reinders TP, Swint JJ, Slate MB. Acquired warfarin resistance and weight reducing diet. Archives of Internal Medicine 141: 507–509, 1981

    PubMed  CAS  Google Scholar 

  • Renowden S, Westermoreland D, White JP, Routledge PA. Oral cholestyramine increase elimination of warfarin after overdose. British Medical Journal 291: 513–514, 1985

    PubMed  CAS  Google Scholar 

  • Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-450209 in the etiology of (S) warfarin drug interactions. Chemical Research and Toxicology 5: 54–59, 1992

    CAS  Google Scholar 

  • Rey AM, Gums JG. Altered absorption of digoxin, sustained-release quinidine, and warfarin with sucralfate administration. DICP: Annals of Pharmacotherapy 25: 745–746, 1991

    PubMed  CAS  Google Scholar 

  • Rhodes RS, Rhodes PJ, Klein C, Sintek CD. A warfarin-piroxicam drug interaction. DICP: Annals of Pharmacotherapy 19: 556–558, 1991

    Google Scholar 

  • Romankiewicz JA, Ehrman M. Rifampin and warfarin: a drug interaction. Annals of Internal Medicine 82: 224–225, 1975

    PubMed  CAS  Google Scholar 

  • Rosenthal AR. Interaction of isoniazid and warfarin. Journal of the American Medical Association 238: 2177, 1977

    PubMed  CAS  Google Scholar 

  • Rosenthal G. Interaction of ascorbic acid and warfarin. Journal of the American Medical Association 215: 1671, 1971

    PubMed  CAS  Google Scholar 

  • Rothstein E, Warfarin effect enhanced by disulfiram (Antabuse). Journal of the American Medical Association 221: 1052–1053, 1972

    PubMed  CAS  Google Scholar 

  • Scnary WL, Lewis, RJ, Rowland M. Warfarin-phenylbutazone interaction in man, a long term multiple dose study. Research Communications in Chemical Pathology and Pharmacology 10: 663–672, 1975

    Google Scholar 

  • Schofield FW. A brief account of a disease of cattle simulating hemorrhagic septicaemia due to feeding sweet clover. Canadian Veterinary Record 3: 74, 1924

    Google Scholar 

  • Schrogie JJ. Coagulopathy and fat-soluble vitamins. Journal of the American Medical Association 232: 19, 1975

    PubMed  CAS  Google Scholar 

  • Schrogie JJ, Solomon HM. The anticoagulant response to bishydroxycoumarin. II. The effect of D-thyroxine, clofibrate and norethandrolone. Clinical Pharmacology and Therapetics 8: 70, 1967

    CAS  Google Scholar 

  • Schulman S, Henrisksson K. Interactions of ibuprofen and warfarin on primary haemostatasis. British Journal of Rheumatology 28: 46–49, 1989

    PubMed  CAS  Google Scholar 

  • Seaton TL, Celum CL, Black DJ. Possible potentiation of warfarin by fluconazole. DICP: Annals of Pharmacotherapy 24: 1177–1178, 1990

    PubMed  CAS  Google Scholar 

  • Self TH. Interaction of sulfisoxazole and warfarin. Circulation 52: 528,1975

    PubMed  CAS  Google Scholar 

  • Sellers EM, Koch-Weser J. Displacement of warfarin from human albumin by diazoxide and ethacrynic, mefenamic, and nalidixic acids. Clinical Pharmacology and Therapeutics 11: 524, 1970

    PubMed  CAS  Google Scholar 

  • Sellers EM, Lang M, Koch-Weser J, Colman RW. Enhancement of warfarin-induced hypoprothrombinemia by ticlofos. Clinical Pharmacology and Therapeutics 13: 911–915, 1972

    PubMed  CAS  Google Scholar 

  • Serlin MJ, Mossman S, Sibeon RG, Tempero KF, Breckenridge AM. Interactins between diflunisal and warfarin. Clinical Pharmacology and Therapeutics 28: 493–498, 1980

    PubMed  CAS  Google Scholar 

  • Serlin MJ, Sibeon RG, Breckenridge AM. Lack of effect of ranitidine on warfarin action. British Journal of Clinical Pharmacology 12: 791–794, 1981

    PubMed  CAS  Google Scholar 

  • Shapiro S, Warfarin sodium derivative: (coumadin sodium). An intravenous hypoprothrombinemia-inducing agent. Angiology 4: 380–390, 1953

    PubMed  CAS  Google Scholar 

  • Shenfield GM, Page M. Potentiation of warfarin action by miconazole oral gel. Australian and New Zealand Journal of Medicine 21: 928, 1991

    PubMed  CAS  Google Scholar 

  • Shetty HG, Fennerty AG, Routledge PA. Clinical pharmacokinetic considerations in the control of oral anticoagulant therapy. Clinical Pharmacokinetics 16: 238–253, 1989

    PubMed  CAS  Google Scholar 

  • Shovick VA, Rihn TL. Decreased hypoprothrombinemic response to warfarin secondary to the warfarin-nafcillin interaction. DICP: Annals of Pharmacotherapy 25: 598–600, 1991

    PubMed  CAS  Google Scholar 

  • Silver BA, Bell WR. Cimetidine potentiation of the hypoprothrombinemic effect of warfarin. Annals of Internal Medicine 90: 348–349, 1979

    PubMed  CAS  Google Scholar 

  • Singleton JD, Conyers L. Warfarin and azathioprine: an important drug interaction. American Journal of Medicine 92: 127, 1992

    Google Scholar 

  • Sioris LJ, Weibert RT, Pentel PR. Potentiation of warfarin anticoagulation by sulfisoxazole. Archives of Internal Medicine 140: 546–547, 1980

    PubMed  CAS  Google Scholar 

  • Slattery JT, Levy G. Effect of ibuprofen on protein binding of warfarin in human serum. Journal of Pharmaceutical Sciences 66: 1060, 1977

    PubMed  CAS  Google Scholar 

  • Spers ASD, Ibashan RS. Increased warfarin requirement during mercaptopurine therapy: new drug interaction. Lancet 2: 221–222, 1974

    Google Scholar 

  • Stringer KA, Switzer DF, Abadier R, Labsack ME, Sedman A, et al. Warfarin. Journal of Clinical Pharmacology 31: 607–610, 1991

    PubMed  CAS  Google Scholar 

  • Sutfin T, Balmer K, Bostrom H, Eriksson S, Hoglund P, et al. Steroselective interaction of omeprazole with warfarin in healthy men. Therapeutic Drug Monitoring 11: 176–184, 1989

    PubMed  CAS  Google Scholar 

  • Tashjian AH, Leddy JP. Agranulocytosis associated with phenindione. Archives of Internal Medicine 105: 121–125, 1960

    PubMed  Google Scholar 

  • Tilstone WJ, Gray JM, Nimmo-Smith RH, Lawson DH. Interaction between warfarin and sulphamethoxazole. Postgraduate Medical Journal 53: 388–390, 1977

    PubMed  CAS  Google Scholar 

  • Toon S, Hopkins KJ, Garstang FM, Aarons L, Sedman A, et al. Enoxacin warfarin interactions: pharmacokinetic and sterochemical aspects. Clinical Pharmacology and Therapeutics 42: 33–41, 1987a

    Google Scholar 

  • Toon S, Hopkins KJ, Garstang FM, Rowland M. Comparative effects of ranitidine and cimentidine on the pharmacokinetics and pharmacodynamics of warfarin in man. European Journal of Clinical Pharmacology 32: 165–172, 1987b

    PubMed  CAS  Google Scholar 

  • Toon S, Low LK, Gibaldi M, Trager WF, O’Reilly RA, et al. The warfarin-sulfinpyrazone interaction: sterochemical considerations. Clinical Pharmacology and Therapeutics 39: 15–24, 1986

    PubMed  CAS  Google Scholar 

  • Trewin VF. A probable interaction between warfarin and metalazone. Pharmaceutical Journal 240: 781–782, 1988

    Google Scholar 

  • Udall JA. Clinical implications of warfarin interactions with five sedatives. American Journal of Cardiology 1: 67–71, 1975

    Google Scholar 

  • Unge P, Svedburg LE, Nordgren A, Blom H, Andersoson T, et al. A study of the interaction of omeprazole and warfarin in anti-coagulated patients. British Journal of Clinical Pharmacology 34: 509–512, 1992

    PubMed  CAS  Google Scholar 

  • Vessell ES, Passananti GT. Anamolous results of studies on drug interactions in man. II. Halofenate (mk-185) and antipyrine, bishydroxycoumarin, and warfarin. Pharmacology 13: 112–127, 1975

    Google Scholar 

  • Wallin BA, Jacknowitz A, Raich PC. Cimetidine and effect of warfarin. Annals of Internal Medicine 90: 993, 1979

    PubMed  CAS  Google Scholar 

  • Watt AH, Stephens MR, Buss DC, Routledge PA. Amiodarone reduces plasma warfarin clearance in man. British Journal of Clinical Pharmacology 20: 707–709, 1985

    PubMed  CAS  Google Scholar 

  • Weibert RT, Lorentz SM, Townsend RJ, Cook CE, Kauber MR. Effect of erythromycin in patients receiving long-term warfarin therapy. Clinical Pharmacology and Therapeutics 41: 224, 1987

    Google Scholar 

  • Wibert RT, McQuade Lorentz S, Townsend RJ, Cook CE, Klauber MR, et al. Effect of erythromycin in patients receiving long-term warfarin therapy. Clinical Pharmacolgy 8: 210–214, 1989

    Google Scholar 

  • Woo KS, Chan K, Pun CO. The mechanisms of warfarin-disopyramide interactions. Circulation 76: 520, 1987

    Google Scholar 

  • Yeh J, Soo S, Summerton C, Richardson C. Potentiation of action of warfarin by itraconazole. British Medical Journal 301: 669, 1990

    PubMed  CAS  Google Scholar 

  • Yip AS, Chow WH, Tai TY, Cheung KL. Adverse effect of topical methylaslicylate ointment on warfarin anticoagulation; an unrecongnized potential hazard. Postgraduate Medical Journal 66: 367–369, 1990

    PubMed  CAS  Google Scholar 

  • Zallman JA, Lee DP, Jeffrey PL. Liquid nutrition as a cause of warfarin resistance. American Journal Hospital Pharmacy 38: 1174, 1981

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

    Michael D. Freedman

  2. Sinai Hospital of Baltimore, Baltimore, Maryland, USA

    Michael D. Freedman & Abiodun G. Olatidoye

Authors
  1. Michael D. Freedman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abiodun G. Olatidoye
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Freedman, M.D., Olatidoye, A.G. Clinically Significant Drug Interactions with the Oral Anticoagulants. Drug-Safety 10, 381–394 (1994). https://doi.org/10.2165/00002018-199410050-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199410050-00003

Keywords

Search

Navigation